Unless the new CEO brings a couple mil in financing with him/her I don't see the change solving all of BIEL's challenges Doc.
AW has constantly been battling a meager checking account while trying to:
* Run clinical trials
* Pay the lawyers
* Pay the Accountants
* Comply with FDA requirements
* Conduct research and development
* Pay employees
* Fund marketing campaigns
* Attend trade shows
* etcetera, etcetera
A lot of shareholders, including myself, are unhappy with the way one thing or another was handled.
How different might things have been done if BIEL was not always counting pennies?
How different would things be with a new CEO and the same resources to work with?
News 
Market Data 
Discover 
